SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Myriad Genetics, Inc. (MYGN)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
2355 65 0 MYGN
Emcee:  s myers Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1730Hi, Harry, Good of you to drop by. Pretty much agree with your assessment of Ftuck-11/28/2005
1729I had never looked at this board before, but in preparing an AD review, I was loNeuroInvestment-11/28/2005
1728from the "zeta likes this stuff" file, and this time it's sort of scaram(o)uche-11/27/2005
1727Myriad Genetics and Abbott Extend Collaboration Tuesday November 22, 6:30 am ET sim1-11/22/2005
1726United States Patent Application 20050250780 Kind Code A1 Qabar, Maher N. ; sim1-11/18/2005
1725United States Patent Application 20050245528 Kind Code A1 Nagula, Gangadhar ;sim1-11/18/2005
1724Hi Tuck ... <<<<< Where's the beef? <<<<< WhJohn McCarthy-11/16/2005
1723OK, according to the abstract, 207 patients were in the study, so that means 168tuck-11/16/2005
1722Ariadne Genomics and Prolexys Partner to Deliver Advanced Pathway Analysis Toolsscaram(o)uche-11/16/2005
1721update, pipeline page....... myriad.com edit: 1882 goes poof. Preclinical liscaram(o)uche-11/15/2005
1720Myriad Genetics' Follow-on Study of Flurizan Demonstrates Cognitive ImprovemJohn McCarthy-11/15/2005
1719over-allot out the door, total in bank from this round is 149M minus the bankscaram(o)uche-11/8/2005
1718>>"Flurizan, we would likely partner," Hockett said, "afterLJM-11/7/2005
1717With Flurizan In Phase III, Myriad Bringing In $130M By Karen Pihl-Carey Staffsim1-11/7/2005
1716but flat out better than last time...... JPM just put a nice hurt on whoever scaram(o)uche-11/4/2005
1715Cancer Res. 2005 Nov 1;65(21):10096-103. Application of embryonic lethal or otscaram(o)uche-11/4/2005
1714Linda S. Wilson....... are you just a token female, or do you serve some nonscaram(o)uche-11/4/2005
171312/28/2004.......... MPC-2130 IND filed 12/09/2004.......... MPC-6827 Iscaram(o)uche-11/4/2005
1712>> What wonderful execution - NOT! << I recently indicated that Melscaram(o)uche-11/4/2005
1711>> What wonderful execution - NOT! << Mr. Meldrum manages his PUBLIscaram(o)uche-11/4/2005
1710What wonderful execution - NOT! Did you see that shorting going on into the cloRobohogs-11/3/2005
1709priced at 18.50, just the right number of shares IMO. should allow for necessarscaram(o)uche-11/3/2005
1708Public release date: 2-Nov-2005 Contact: Rex Graham ragraham@ucsd.edu 858-822-3scaram(o)uche-11/2/2005
1707Meldrum's salary continues to go thru the roof, while share price remains lascaram(o)uche-11/2/2005
1706United States Patent 6,960,431 Morham , et al. November 1, 2005 -------scaram(o)uche-11/2/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News